How to deal with the complications of OP therapy. #ACR18 @RheumNow Abstract 4M092 pic.twitter.com/ZvzbBNR162
— William Shergy (@WilliamShergy) October 22, 2018
RheumNow expanded twitter coverage of the ACR 2018 Annual meeting sponsored in part by Horizon Pharma. All content chosen and distributed by RheumNow and its faculty.
— Dr. John Cush (@RheumNow) October 22, 2018
Dr. Kevin Winthrop: Last year influenza B accounted for about 50% of flu, and 95% of the B was Yamagata strain which is NOT included in the high-dose flu vaccine, only the quadrivalent. Makes choosing which one to give our patients very difficult! #ACR18 #CleClinicRheum pic.twitter.com/xwCxvQTrjJ
— Elizabeth Kirchner (@BetsyKirch) October 22, 2018
Great talk on spondyloarthritis :
In patients with active or stable AS on TBF inhibition we recommend against co- treatment with low dose Methotrexate( can be considered with infliximab)#ACR18— Negin Ezzati (@EzzatiNegin) October 22, 2018
Oculobulbar involvement important clue in distinguishing PD-1 inhibitor necrotizing myopathy from other necrotizing myopathy. #ACR18 Thieves’ Market pic.twitter.com/DC0RibaA7q
— Julie Jones (@JonesN4Rheum) October 22, 2018
K Winthrop: if it is too hard or cause to much stress – don’t worry about holding MTX or timing of vaccine after RTX. Just give the flu vaccine and move on. @rheumnow #acr18
— k dao (@KDAO2011) October 22, 2018
RheumNow expanded twitter coverage of the ACR 2018 Annual meeting sponsored in part by Eli Lilly & Company. All content chosen and distributed by RheumNow and its faculty.
— Dr. John Cush (@RheumNow) October 22, 2018
Abstract 1688: changes in heart rate variability (HRV) correlate with lupus disease activity and flaring. One of my favorite topics! Thanks @alhkim for pointing me to this poster. #ACR18 @RheumNow pic.twitter.com/IZ4eDijwqJ
— Dr. Paul Sufka (@psufka) October 22, 2018
To me SBE is a MUST rule out in every new ANCA renal presentation. We need. To know the extent and mechanisms @VasculitisFound @CleClinRheum #vasculitis @ACR18 @HealioRheum @RheumNow https://t.co/bPvRwIHFje
— Leonard Calabrese (@LCalabreseDO) October 22, 2018
low neutrophil-to-lymphocyte ratio pre-checkpoint inhibitor therapy may predict development of rheumatic irAE – so interesting @drdavidliew ! @RheumNow #ACR18 @HealioRheum
— Cassandra Calabrese (@CCalabreseDO) October 22, 2018
In Kevin Winthrop on vaccinations noted only 30-40% healthcare workers in Oregon actually got their flu vaccine .. vote: have u had your flu vaccine? @rheumnow #acr18 https://t.co/7KEmTZgDXd
— k dao (@KDAO2011) October 22, 2018
K Winthrop: people who have higher BAFF levels don’t need to hold MTX for flu vaccine, they respond well, but he admits that he does not know how to commercially test for this in pts. @rheumnow #acr18
— k dao (@KDAO2011) October 22, 2018
RheumNow expanded twitter coverage of the ACR 2018 Annual meeting sponsored in part by Novartis. All content chosen and distributed by RheumNow and its faculty.
— Dr. John Cush (@RheumNow) October 22, 2018
This is why combination DMARD therapy works by J Kremer: HCQ can increase active tubular absorption of MTX when used in combo; SSZ inhibits uptake of MTX AT RFC @rheumnow #acr18
— k dao (@KDAO2011) October 22, 2018
#ACR18 #1866 Genovese: Incidence of IBD in Ps/PsA treated with Ixekizumab in 15 RCTs. All trials excluded *active* IBD. Incidence rates low (0.25/1000pt-yrs for flare; 1.35/1000py for new IBD); many of these continued in trial.
Risk of IBD real, but low. @RheumNow pic.twitter.com/JZRyCKmICt
— ǝlʇʇıɥʍ ɯɐs (@samwhittle) October 22, 2018
Abstract 1636
ASAS pt cohort-
Erosions and fatty lesions remain the most common and specific MRI lesions in AxSpA.#ACR18 @rheumnow pic.twitter.com/IlkA3VjPUx— Julio Gonzalez (@japaoli19) October 22, 2018
In women with #SLE, erythrocyte bound C4d, a marker of classical complement pathway activation, is higher during the first trimester of pts who go on to develop #AdversePregnancyOutcomes including fetal death in the 2nd/3rd trimesters. Abstract1855 #DrJillBuyon #ACR18 @RheumNow
— Nicole Bitencourt (@NicoleBitencou5) October 22, 2018
J Kremer: MTX pneumonitis trifecta: cough, fever, SOB. Hint— you know it is MTX pneumonitis if symptoms disappear when MTX stopped at first signs of symptoms @rheumnow #acr18
— k dao (@KDAO2011) October 22, 2018
#ACR18 #1868 Dr Deodhar: Certolizumab vs PBO for nrAxSpA over 52 wks. CRP+ or MRI+ patients. Primary OM ASDAS-MI 47% vs 7% at 52w. No new safety signals.
Long PBO period shows nrAxSpA is not self-remitting.More evidence that nrAxSpA is ‘real’ and responds to TNFi. @RheumNow pic.twitter.com/uCMx4fRwsd
— ǝlʇʇıɥʍ ɯɐs (@samwhittle) October 22, 2018
In #SLE pregnancies, ONLY 25% of women were on ASA (and only 10% of pregnant black women w SLE were on ASA) in the SLICC registry. #ASAinALLlupuspregnancies as shown to decrease pre-exlampsia. Abstract1856 Dr. Arielle Mendel #ACR18 @RheumNow
— Nicole Bitencourt (@NicoleBitencou5) October 22, 2018
#ACR18 #1869 Dr Kivitz: 3y results from MEASURE3 Secukinumab for AS.
>80% retention at 3yrs. Sustained ASAS20/40. 300mg dose maybe better than 150mg. Serious infections rare, candida rare (0.7% for each dose).
No imaging outcomes.Reassuring from safety perspective.@RheumNow pic.twitter.com/UaehZOXY8w
— ǝlʇʇıɥʍ ɯɐs (@samwhittle) October 22, 2018
Abstract 1631
20% incidence of uveitis in SpA with IBD phenotype having the highest incidence #ACR18 @rheumnow pic.twitter.com/UQXKpAcapj— Julio Gonzalez (@japaoli19) October 22, 2018
Hey #ACR18! When prescribing anti-IL 17 for AS or PsA, do you consider possibility of IBD as a side effect before prescribing? @RheumNow
— Brittany A (@MissbeeMD) October 22, 2018
Abstract 1628
They are not the same disease and this will be more clinically relevant as the treatment options grow.
HLAB27+/Male and younger age->AS#ACR18 @rheumnow pic.twitter.com/h6FBQOlzVo— Julio Gonzalez (@japaoli19) October 22, 2018
Great Pearl by Dr J Kremer: if a patient complains about hair loss with MTX, add leucovorin (but don’t administer same day as MTX). He acknowledged there is no data for this- just experience @rheumnow #acr18
— k dao (@KDAO2011) October 22, 2018
Pooled analysis of immmunogenicity showed presence of antidrug Abs decreased ACR20 response rates and DAS28 overall for most agents (little effect on Adalimumab) @RheumNow #ACR18 pic.twitter.com/w3uh5gEAsy
— Dr. Arthur Lau (@ArthurRheum) October 22, 2018
In a systematic review of 12 studies of paternal exposure to MTX (including 265 fathers), NO association was found with congenital malformations. Thus at present we have #noevidencetoavoidMTX in men trying to conceive. Abstract1853 Dr. Thomas Jensen. #ACR18 @RheumNow
— Nicole Bitencourt (@NicoleBitencou5) October 22, 2018
Abstract L10
Combo LEF/HCQ shows improvements on always difficult to treat Sjogrens Syndrome markers of disease activity #ACR18 @rheumnow pic.twitter.com/flQoPABsa2— Julio Gonzalez (@japaoli19) October 22, 2018
#ACR18 @RheumNow abs 1711. Lupus low disease activity – LLDAS achieved in 14.4% of patients in BLISS trial dataset. A hard target to get to, even with proven therapies. Miles to go before we sleep! pic.twitter.com/EjpJY9OBPs
— Ian N Bruce (@Lupusdoc) October 22, 2018
J Kremer: note that time it takes for MTX-PG to reach steady state is 27.5 weeks. Let pts know it might take MTX 6 months to see clinical effects. Also, a change in the dose of MTX may take more than a couple of weeks to see its effect. @rheumnow #acr18
— k dao (@KDAO2011) October 22, 2018
AbstractL11
Not surprisingly Etanercept monotherapy was superior to MTX mono and as good as combo Tx in PsA but MTX mono did have decent ACR response at W16#ACR18 @rheumnow pic.twitter.com/QzZhZMDE6u— Julio Gonzalez (@japaoli19) October 22, 2018
#ACR18 @RheumNow abs 1706 hat off to @LupusOrg constructing a self-Mx programme for #SLE based on key themes for intervention. pic.twitter.com/iKg9nbg9br
— Ian N Bruce (@Lupusdoc) October 22, 2018